Real Heart (HEART) - Net Assets

Latest as of June 2025: Skr74.35 Million SEK ≈ $8.00 Million USD

Based on the latest financial reports, Real Heart (HEART) has net assets worth Skr74.35 Million SEK (≈ $8.00 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr87.94 Million ≈ $9.46 Million USD) and total liabilities (Skr13.59 Million ≈ $1.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Real Heart carry for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr74.35 Million
% of Total Assets 84.54%
Annual Growth Rate 36.11%
5-Year Change -6.07%
10-Year Change 1028.55%
Growth Volatility 331.37

Real Heart - Net Assets Trend (2010–2024)

This chart illustrates how Real Heart's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Real Heart for the complete picture of this company's asset base.

Annual Net Assets for Real Heart (2010–2024)

The table below shows the annual net assets of Real Heart from 2010 to 2024. For live valuation and market cap data, see market cap of Real Heart.

Year Net Assets Change
2024-12-31 Skr67.34 Million
≈ $7.25 Million
-17.92%
2023-12-31 Skr82.04 Million
≈ $8.83 Million
-15.98%
2022-12-31 Skr97.65 Million
≈ $10.51 Million
-12.26%
2021-12-31 Skr111.29 Million
≈ $11.98 Million
+55.23%
2020-12-31 Skr71.69 Million
≈ $7.72 Million
+21.51%
2019-12-31 Skr59.00 Million
≈ $6.35 Million
+205.70%
2018-12-31 Skr19.30 Million
≈ $2.08 Million
-29.87%
2017-12-31 Skr27.52 Million
≈ $2.96 Million
+69.86%
2016-12-31 Skr16.20 Million
≈ $1.74 Million
+171.52%
2015-12-31 Skr5.97 Million
≈ $642.14K
-20.41%
2014-12-31 Skr7.50 Million
≈ $806.85K
+1285.74%
2013-12-31 Skr541.04K
≈ $58.22K
-32.25%
2012-12-31 Skr798.57K
≈ $85.94K
-1.66%
2011-12-31 Skr812.04K
≈ $87.39K
-9.64%
2010-12-31 Skr898.64K
≈ $96.71K
--

Equity Component Analysis

This analysis shows how different components contribute to Real Heart's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 16960153800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Skr10.36 Million 15.39%
Other Components Skr226.66 Million 336.59%
Total Equity Skr67.34 Million 100.00%

Real Heart Competitors by Market Cap

The table below lists competitors of Real Heart ranked by their market capitalization.

Company Market Cap
P3 Health Partners Inc
NASDAQ:PIII
$9.58 Million
Perfect Moment Ltd.
NYSE MKT:PMNT
$9.58 Million
Entero Therapeutics, Inc.
NASDAQ:ENTO
$9.58 Million
Titan Logix Corp.
V:TLA
$9.58 Million
Akkhie Prakarn Public Company Limited
BK:AKP
$9.57 Million
CD Private Equity Fund I
AU:CD1
$9.57 Million
Thai Wire Products Public Company Limited
BK:TWP
$9.57 Million
Jaya Trishindo Tbk PT
JK:HELI
$9.57 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Real Heart's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 82,037,974 to 67,340,121, a change of -14,697,853 (-17.9%).
  • Net loss of 34,350,000 reduced equity.
  • New share issuances of 19,585,388 increased equity.
  • Other comprehensive income increased equity by 138,814,289.
  • Other factors decreased equity by 138,747,530.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr-34.35 Million -51.01%
Share Issuances Skr19.59 Million +29.08%
Other Comprehensive Income Skr138.81 Million +206.14%
Other Changes Skr-138.75 Million -206.04%
Total Change Skr- -17.92%

Book Value vs Market Value Analysis

This analysis compares Real Heart's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.55x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 339.89x to 0.55x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 Skr0.05 Skr17.80 x
2011-12-31 Skr0.05 Skr17.80 x
2012-12-31 Skr0.05 Skr17.80 x
2013-12-31 Skr0.03 Skr17.80 x
2014-12-31 Skr0.44 Skr17.80 x
2015-12-31 Skr0.35 Skr17.80 x
2016-12-31 Skr0.86 Skr17.80 x
2017-12-31 Skr1.20 Skr17.80 x
2018-12-31 Skr0.86 Skr17.80 x
2019-12-31 Skr208.01 Skr17.80 x
2020-12-31 Skr206.17 Skr17.80 x
2021-12-31 Skr2.24 Skr17.80 x
2022-12-31 Skr131.65 Skr17.80 x
2023-12-31 Skr56.66 Skr17.80 x
2024-12-31 Skr32.56 Skr17.80 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Real Heart utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -51.01%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.24x
  • Recent ROE (-51.01%) is below the historical average (-28.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 -13.00% -973258.33% 0.00x 1.08x Skr-206.65K
2011 -10.66% -8659500.00% 0.00x 1.08x Skr-167.80K
2012 -1.69% 0.00% 0.00x 1.55x Skr-93.33K
2013 -47.69% -58239.28% 0.00x 2.56x Skr-312.10K
2014 -22.54% -746.94% 0.03x 1.11x Skr-2.44 Million
2015 -25.66% -1034.08% 0.02x 1.11x Skr-2.13 Million
2016 -23.97% -2927.48% 0.01x 1.25x Skr-5.50 Million
2017 -49.94% -1773.49% 0.02x 1.23x Skr-16.50 Million
2018 -45.89% -7955.31% 0.00x 1.42x Skr-10.79 Million
2019 -12.36% 0.00% 0.00x 1.13x Skr-13.19 Million
2020 -12.30% 0.00% 0.00x 1.09x Skr-15.99 Million
2021 -9.42% 0.00% 0.00x 1.06x Skr-21.61 Million
2022 -14.33% -139880.00% 0.00x 1.23x Skr-23.75 Million
2023 -82.86% 0.00% 0.00x 1.25x Skr-76.18 Million
2024 -51.01% 0.00% 0.00x 1.24x Skr-41.08 Million

Industry Comparison

This section compares Real Heart's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $171,567,428
  • Average return on equity (ROE) among peers: -27.92%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Real Heart (HEART) Skr74.35 Million -13.00% 0.18x $9.58 Million
Acarix A/S (ACARIX) $15.12 Million -127.02% 0.21x $33.84 Million
Arcoma AB (ARCOMA) $48.66 Million 5.27% 0.68x $11.55 Million
Bactiguard Holding AB (publ) (BACTI-B) $387.11 Million -0.84% 0.62x $61.64 Million
BICO Group AB (BICO) $2.31 Million 0.00% 2.47x $159.82 Million
Boule Diagnostics AB (BOUL) $295.74 Million 7.87% 0.93x $14.38 Million
CellaVision AB (CEVI) $887.58 Million 17.25% 0.23x $311.10 Million
Clinical Laserthermia Systems AB (publ) (CLS-B) $26.09 Million -70.24% 0.12x $11.57 Million
Chordate Medical Holding AB (CMH) $25.64 Million -77.06% 0.22x $29.05K
C-Rad AB (publ) (CRAD-B) $29.82 Million -34.38% 0.50x $86.08 Million
Duearity AB (DEAR) $-2.39 Million 0.00% 0.00x $331.97K

About Real Heart

ST:HEART Sweden Medical Devices
Market Cap
$9.58 Million
Skr88.98 Million SEK
Market Cap Rank
#26978 Global
#591 in Sweden
Share Price
Skr17.80
Change (1 day)
-1.66%
52-Week Range
Skr12.85 - Skr29.00
All Time High
Skr1625.78
About

Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis to fix the sternum after open-chest surgery. The company was founded in 1999 and is bas… Read more